STRO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ST

Mkt Cap

$181.2M

Volume

318.57K

Next Earnings

November 5th

Loading chart

ST

STROSutro Biopharma, Inc.

STRO

Pay with—

Available Balance0.00

ST

Mkt Cap

$181.4M

Volume

318.56K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026Sutro Biopharma announced promising preclinical data for its ADC pipeline at AACR 2026, with STRO-004 demonstrating robust antitumor activity across multiple solid tumor models and improved efficacy versus benchmark ADCs. The company also presented data for STRO-006 and STRO-227, with IND submissions planned for 2026. Partner Astellas presented results from ASP2998, a TROP2-targeted immunostimulatory ADC that entered clinical trials earlier in 2026.GlobeNewswire Inc. · Apr 19, 2026

Sutro Biopharma Announces Pricing of $110.0 million Underwritten OfferingSutro Biopharma announced the pricing of an underwritten offering of 7,868,383 shares at $13.98 per share, generating approximately $110 million in gross proceeds. The offering includes participation from multiple investors and is expected to close on February 11, 2026. Proceeds will be used for research, clinical development, manufacturing, and general corporate purposes.GlobeNewswire Inc. · Feb 10, 2026

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid TumorsSutro Biopharma initiated a Phase 1 clinical trial for STRO-004, a next-generation antibody-drug conjugate targeting tissue factor in various solid tumors. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across multiple cancer types.GlobeNewswire Inc. · Dec 3, 2025

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D DaySutro Biopharma announced the initiation of its Phase 1 study for STRO-004, a Tissue Factor ADC, and selected PTK7 as the target for its first dual-payload candidate STRO-227, showcasing its innovative antibody-drug conjugate platform.GlobeNewswire Inc. · Nov 12, 2025

Sutro Biopharma Announces Participation at the 16th Annual World ADC ConferenceSutro Biopharma will present preclinical data on advanced antibody-drug conjugates (ADCs) at the 16th Annual World ADC Conference, highlighting innovations in dual-payload ADCs and cell-free manufacturing platforms to potentially improve cancer treatment.GlobeNewswire Inc. · Nov 3, 2025

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market MilestoneThe FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.Benzinga · Aug 28, 2025

New Cancer Treatments Spark Hope as Traditional Funding Faces UncertaintyThe article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.Benzinga · May 1, 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025Sutro Biopharma presented data from the dose-optimization portion of the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer. The data showed encouraging antitumor activity and a consistent safety profile across dose levels.GlobeNewswire Inc. · Mar 15, 2025

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology PlayersThe oncology industry has seen significant progress, with cancer deaths falling by 33% in the last 30 years. Several key players, including Oncolytics Biotech, Novartis, Lantheus Holdings, Sutro Biopharma, and Zymeworks, have reported promising developments in their cancer research and treatments.Benzinga · Sep 19, 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024Sutro Biopharma, a clinical-stage oncology company, will host a Research Forum to highlight its pipeline of next-generation antibody drug conjugates (ADCs) on October 10, 2024.GlobeNewswire Inc. · Sep 11, 2024

to start trading

ST

STROSutro Biopharma, Inc.

STRO

Pay with—

Available Balance0.00

Your PositionYou don't own any STRO yet.

Related Tickers

Earnings